百奥赛图是一家创新技术驱动新药研发的国际性医药科技股份有限公司，专注技术创新、持续新药产出、守护人类健康。基于百奥赛图自主研发并拥有完全独立知识产权的全人抗体RenMab、RenLite、RenNano小鼠，将单细胞抗体发现技术平台、高效的基因编辑模型开发平台、规模化动物模型供应平台、快速的动物体内外药效评价平台、强大的临床开发能力有机整合在一起，形成了独具特色、涵盖药物研发全流程的新药研发体系。公司成功战略转型为Biotech，未来将更聚焦于创新抗体药物研发。随着规模化抗体药物研发-“千鼠万抗”计划的实施，百奥赛图将携手全球合作伙伴，共同加速新药研发。百奥赛图总部位于北京，在江苏海门、美国波士顿、上海等地设有分支机构，员工数共计1050人，全资子公司祐和医药专注于临床开发。
专注技术创新、持续新药产出、守护人类健康
成为全球新药发源地
Heat stroke has increased in frequency worldwide in recent years and continues to have a high morbidity and mortality. Identification of the mechanisms mediating heat stoke is important and necessary. Our preliminary study revealed heat stress (HS)-induce
We have identified an epidermal cancer stem (ECS) cell population that drives formation of rapidly growing and highly invasive and vascularized tumors. VEGF-A and neuropilin-1 (NRP-1) are highly expressed in ECS cell tumors and VEGF-A/NRP-1 interaction is
